



Attorney Docket No. 037003-0280623  
Client Ref. No.: 1999430-0466CP3

1614  
RECEIVED  
TECH CENTER 21 2003  
1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hanna, et al.

Serial No. 09/855,717

Filed: May 16, 2001

For: TREATMENT OF B CELL  
MALIGNANCIES USING  
COMBINATION OF B CELL  
DEPLETING ANTIBODY AND  
IMMUNE MODULATING  
ANTIBODY RELATED  
APPLICATIONS

Art Unit: 1614

Examiner: Not yet assigned

Certificate of Mailing

I, Patricia Munoz, hereby certify that this paper or fee is being deposited with the United States Postal Service as Express Mail Post Office to Addressee service (Mailing Label No. EV 159 087 720 US) under 37 C.F.R. § 1.10 on the date indicated below and is addressed to the Hon. Commissioner of Patents and Trademarks, Washington D.C. 20231.

By: Patricia Munoz  
Patricia Munoz

Date: April 14, 2003

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with the Applicants' duty under 37 C.F.R. §§1.97-98, the following information is brought to the attention of the Examiner. The items are listed on the attached form PTO-1449 and copies of the references are attached for the Examiner's convenience.

Certain of these references were cited in one or more of the International Search Reports for PCT/US00/30426, PCT/US01/15677, PCT/US02/02620 and PCT/US02/02621, which are related to the present application in that all claim priority from, *inter alia*, certain earlier filed United States applications. Copies of the International Search Reports are attached.

The items identified in this Information Disclosure Statement may or may not be "material" pursuant to 37 CFR §1.56 and the submission thereof by Applicants shall not be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 C.F.R. §1.97(h)), or even qualifies as "prior


art" under 35 U.S.C. §102 with respect to this invention unless specifically designated by Applicants as such.

The filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information, as defined in 37 C.F.R. §1.56, exists.

The Commissioner is hereby authorized to charge any fee, including any fee due with this submission, if the attached check(s) is in the wrong amount or otherwise improper or missing, that may be due in connection with this and the attached papers, or with this application during its entire pendency to or to credit any overpayment to Deposit Account 03-3975, Order No. 037003-0280623.

Respectfully submitted,


PILLSBURY WINTHROP LLP

By   
Suzanne L. Biggs  
Registration No. 30,158

Dated: April 14, 2003

Address all correspondence to:  
11682 El Camino Real, Suite 200  
San Diego, CA 92130  
Tel: (858) 509-4095  
Fax: (858) 509-4010

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office



Atty. Dkt. No.	M#	Client Ref.
	037003-0280623	1999-30-0466CP3

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: Hanna, et al.

Appln. No.: 09/855,717

Filing Date: May 16, 2001

Date: April 14, 2003

Page 1 of 2

Examiner: TBA

Group Art Unit: 1614

## U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR 601,138	03/1898	Hall			
	BR 5,736,137	04/1998	Anderson, et al.	424	133.1	
	CR 5,916,560	06/1999	Larsen, et al.	424	154.1	
	DR 6,001,358	12/1999	Black, et al.	424	154.1	
	ER					

## FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclose	No
	FR WO 98/19706	05/1998	PCT	Anderson, et al.				
	GR WO 98/39026	09/1998	PCT	Kalled, et al.				
	HR WO 98/56417	12/1998	PCT	Harlan, et al.				
	IR WO 00/44788	08/2000	PCT	Braslawsky, et al.				
	JR WO 01/34194 A1	05/2001	PCT	Hanna, et al.				
	KR WO 01/89567 A1	11/2001	PCT	Anderson, et al.				
	LR WO 02/04021 A1	01/2002	PCT	Hanna, et al.				


## OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

MR	Akpek G., et al., Chemathrapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma, Cancer, 86(7):1368-1376 (Oct. 1, 1999) [XP-002906151]				
NR	Benoit, N., et al., Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and either CD19, CD20, CD95 or surface immunoglobulin, Immunopharmacology 35:129-139 (1996) [XP-002213373]				
OR	Buske, C., et al. Monoclonal antibody therapy for B cell Non-Hodgkin's lymphomas: Emerging concepts of a tumour-targeted strategy, European Journal of Cancer, 35(4):549-557 (1999) [XP-001010018]				
PR	Dallaire, B., et al., New aspects of treatment of B-cell non-Hodgkin's lymphomas with monoclonal antibodies. IDEC-C2B8 (Rituximab): Biology and preclinical studies, Journal of Molecular Medicine, Springer Verlag, DE, 75(7):B230-B231 (1997) [XP-000952701]				
QR	Davis, J., et al., Results of a phase I, single-dose, dose-escalating trial of a humanized anti-CD40L monoclonal antibody (IDEC 131) in patients with systemic lupus erythematosus (SLE), Arthritis and Rheumatism, Lippincott, Philadelphia, US, 42(9):S281 (September 1999) [XP-002161703]				
RR	Furman, R., et al., Modulation of NF-kB activity and apoptosis in chronic lymphocytic leukemia B cells, The Journal of Immunology, 164(4):2200-2206 (February 15, 2000) [XP-002203960]				
SR	Gelber, E., et al., Effect of immunosuppressive agents on the immunogenicity and efficacy of an immunotoxin in mice, Clinical Cancer Research, 4(5):1297-1304 (May 1998) [XP-002161701]				

RECEIVED

APR 21 2003

TECH CENTER 1000/2000

	TR	Ghetie, M., et al., Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest, Blood, 83(5):1329-1336 (March 1, 1994) [XP-002088438] ✓				
	UR	Gottlieb, A., et al., Results of a single-dose, dose-escalating trial of an anti-B7.1 monoclonal antibody (IDEC-114) in patients with psoriasis, Journal of Investigative Dermatology, 114(4):840 (April 2000) [XP-002203912] ✓				
	DR	Green, K., et al., Evidence for a continued requirement of rCD40/CD40 ligand (CD154) interactions in the progression of LP-BM5 retrovirus-induced murine aids, Virology, 241(2):260-268 (February 15, 1998) [XP-002161702] ✓				
	WR	Hariharan, K., et al., Therapeutic activity of IDEC-114 (Anti-CD80) and Rituximab (Rituxan®) in B-cell lymphoma, Blood, 98(11, part 1):608a (November 16, 2001) [XP-001079527] ✓				
	XR	Heath, A., et al., Antibodies to murine CD40 stimulate normal B lymphocytes but inhibit proliferation of B lymphoma cells, Cellular Immunology, 152:468-480 (1993) [XP-002110518] ✓				
	YR	Juweid, M., et al., Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody, Cancer Research (Suppl.), 55:5899s-5907s (December 1, 1995) [XP-002070325] ✓				
	ZR	LaPlante, S., et al., Cost-efficacy evaluation of fludarabine phosphate in the treatment of chronic lymphocytic leukemia refractory to other therapies, European Journal of Cancer, Pergamon Press, Oxford, GB, 33:S29-30 (November 1997) [XP-004284486] ✓				
	AAR	Levy, R., 1999 keystone symposium on B lymphocyte biology and disease: B cell malignancy II session, Biochimica Et Biophysica Acta, 1424(2-3):R43-4 (October 29, 1999) [XP-000982627] ✓				
	BBR	O'Brien S., et al., Phase I/II study of Rituxan in chronic lymphocytic leukemia (CLL), Blood, 92(10 supp. 01, prt 1/2):105A (November 15, 1998) [XP-001062170] ✓				
	CCR	Ouaaz, F., et al., Growth arrest and terminal differentiation of leukemic myelomonocytic cells induced through ligation of surface CD23 antigen, Blood, 84(9):3095-3104 (November 1994) [XP-001079834] ✓				
	DDR	Pathan, N., et al., Induction of apoptosis by IDEC-152 (Anti-CD23) in lymphoma cells, Blood, 98(11, part 1):367a (November 16, 2001) [XP-001079733] ✓				
	EER	Press, O., et al., Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody, Journal of Clinical Oncology, 7(8):1027-1038 (August 1989) [XP-002936241] ✓				
	FFR	Romano, M., et al., Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells, Blood, 92(3):990-995 (August 1, 1998) ✓				
	GGR	Tutt, A., et al., Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors, The Journal of Immunology 161(6):3176-3185 (September 15, 1998) [XP-002213374] ✓				
	HHR	Silber, R., et al. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs, Blood, 84(10):3440-3446 (November 15, 1994) ✓				
	IIR	Wrone-Smith T., Inhibition of costimulatory molecules as a means of treating a murine CD4+ T-cell dependent B-cell lymphoma, Database Cancerlit 'Online!' (retrieved from STN Database accession no. 96606486) [XP-002203913] abstract and Dissertation Abstracts Int. 'B', 56(2):736 (1995) ISSN: 0419-4217				

Examiner

Date Considered:

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.